By integrating crystallographic data with computational modeling, we bridge the gap between basic structural biology and therapeutic discovery, offering a foundation for future studies aimed at targeting SOD1 in ALS and other neurodegenerative diseases. This evidence concerns the gene SOD1 and neurodegenerative disease.